对此，李佳鸿回应称，东宝集团一直致力于降低其质押的公司的股份，虽然目前质押率较高，主要原因是东宝集团投资的项目周期长，资金仍有占用，给偿还债务带来一定的压力和风险。但从东宝集团的长远发展前景上看，现投入的项目及在研的产品，目前已无需大的资金投入，并且将逐步进入回收期，经营能力逐渐向好。①The high pledge ratio of the controlling shareholder of Tonghua Dongbao has been questioned, the company's chairman Li Jiahong stated that it was caused by the long investment cycle of Dongbao Group's projects. ②In terms of performance, Li Jiahong expects that the company's revenue will gradually recover in the second half of the year. ③The company also introduced the sales situation of new products.
On October 10th, Caijing News Agency (Reporter He Fan) reported that the controlling shareholder of Tonghua Dongbao (600867.SH) (Dongbao Group) pledged 86.94% of its total shareholding for pledging. Faced with such a high pledge ratio, the company's chairman Li Jiahong explained to investors at the earnings conference that this was due to the long investment cycle of Dongbao Group's projects, but future large capital inputs were no longer necessary. Tonghua Dongbao also faces the challenge of declining performance. Li Jiahong expects that the company's revenue will gradually recover quarter by quarter in the second half of the year. In addition, the company also introduced the sales situation of new products.
According to the semi-annual report, Dongbao Group pledged a total of 514 million shares, accounting for 86.94% of the total shareholding of the company and 25.96% of the total share capital of the company. Faced with a high proportion of pledge, some investors raised questions at the earnings conference.
In response, Li Jiahong stated that Dongbao Group has been committed to reducing the pledged shares of the company. Although the current pledge ratio is high, the main reason is the long investment cycle of Dongbao Group's projects, which still occupy funds and bring certain pressure and risks to debt repayment. However, looking at the long-term development prospects of Dongbao Group, the current projects and products under development no longer require significant capital investment, and will gradually enter the recovery period with improving operational capabilities.
In addition, regarding the company's performance, Li Jiahong predicted: 'In the second half of the year, the company's shipments and sales work will gradually return to normal, and revenue will also recover quarter by quarter. With the renewal of insulin centralized procurement in various provinces and cities in the second half of the year, the company will obtain a considerable amount of procurement volume and quickly accelerate the access of the company's insulin similar products to hospitals nationwide, continuing to focus on the sales of insulin similar products. At the same time, the company will continue to increase its investment in grassroots markets, retail channels, and private hospitals.'
On the other hand, Tonghua Dongbao's gross margin in the first half of the year declined by over 45%, while sales expenses increased by 12.49% year-on-year. In response, the company's secretary Su Fan explained to the Caijing News Agency reporter that in the first half of the year, the company focused on the sales of insulin analog products (Glargine, Regular Insulin, Premixed Regular Insulin); and secondly, new products GLP-1 Liraglutide, Englitazone, and Sitaliptin have also started to be marketed and sold, resulting in an increase in sales personnel compared to the same period last year, and corresponding increase in sales expenses.
In terms of new products, Li Jiahong informed investors that in the first half of the year, the company mainly promoted the listing and hospital access of Liraglutide in various provinces. They have completed the admission work of over 2000 hospitals (including 1000+ tertiary hospitals) and have already achieved sales revenue. Secondly, Su Fan told the Caijing News Agency reporter that starting from the first half of this year, Liraglutide and Englitazone have contributed to sales revenue, and Sitaliptin has also generated sales revenue since the second half of this year.
Regarding new products, Li Jiahong told investors that in the first half of the year, the company mainly promoted the listing of Liraglutide in various provinces and hospital access work. They have completed the admission work of over 2000 hospitals (including 1000+ tertiary hospitals) and have already achieved sales revenue. Moreover, Su Fan informed the Caijing News Agency reporter that starting from the first half of this year, Liraglutide and Englitazone have contributed to sales revenue, and Sitaliptin has also generated sales revenue since the second half of this year.
